Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012850 | 1.00 | ADRB2 (0.56) | ADRB2 | |
| SCHEMBL13589426 | 0.92 | ADRB2 (0.53) | ADRB2 | |
| SCHEMBL14422856 | 0.92 | ADRB2 (0.46) | ADRB2 | |
| SCHEMBL4253565 | 0.92 | ADRB2 (0.46) | ADRB2 | |
| SCHEMBL4255093 | 0.92 | ADRB2 (0.51) | ADRB2 | |
| SCHEMBL4255091 | 0.92 | ADRB2 (0.51) | ADRB2 | |
| SCHEMBL4253746 | 0.91 | ADRB2 (0.52) | ADRB2 | |
| SCHEMBL4258497 | 0.91 | ADRB2 (0.71) | ADRB2 | |
| SCHEMBL4258495 | 0.91 | ADRB2 (0.71) | ADRB2 | |
| SCHEMBL4392422 | 0.91 | ADRB2 (0.56) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1624868-B9 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2009-08-12 | — | — | EP | claimed |
| EP-1624868-B1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | claimed |
| US-7629358-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1624868-B9 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2009-08-12 | — | — | EP | disclosed |
| US-7482487-B2 | Phenylaminoethanol derivatives as β2 receptor agonists | PFIZER INC (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1624868-B1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | BROWN ALAN D | 2007-11-15 | — | — | US | disclosed |
| US-7268147-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1727789-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | Pfizer Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2006051373-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| US-20060106107-A1 | L-tartrate salt of N-1-Adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl] phenyl}acetamide | JAMES KIM | 2006-05-18 | — | — | US | disclosed |
| EP-1624868-A1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL!PHENYL DERIVATIVES AS BETA2 AGONISTS | Pfizer Limited (GB) | 2006-02-15 | — | — | EP | disclosed |
| US-20050234097-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| WO-2005090287-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| EP-1577292-A1 | Phenylaminoethanol derivatives as beta2 receptor agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004100950-A1 | ‘(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)-PROPYL!PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| US-20040229904-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1477167-A1 | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106107-A1 | L-tartrate salt of N-1-Adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl] phenyl}acetamide | ASPH, SLC6A12, AASDHPPT | ADRB2 498/4885 |
| US-20050234097-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B2, CYP11B1 | ADRB2 731/4885 |
| US-20040229904-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B1, CYP11B2 | ADRB2 901/4885 |
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.